Mylan starts Ph III trials for generics of Advair Diskus and insulin analog to Lantus

16 September 2014

US generic drugs major Mylan (Nasdaq: MYL) says it is initiating Phase III clinical trials for its generic version of GlaxoSmithKline's (LSE: GSK) Advair Diskus (salmeterol and fluticasone propionate combination) and its insulin analog to Sanofi's (Euronext: SAN) Lantus (insulin glargine).

In October, Mylan will commence a Phase III clinical trial to evaluate the equivalence of its product to Advair Diskus when administered by inhalation in adult asthma patients. The Seretide/Advair (salmeterol and fluticasone) franchise generated second-quarter sales of £1,095 million ($1.78 billion) for GSK, down 12% year-on-year.

Two Phase III clinical trials for Mylan's insulin analog program already are underway. In August, the company initiated INSTRIDE 1 and INSTRIDE 2 to compare the efficacy and safety of Mylan's insulin glargine with that of Lantus in both type 1 and type 2 diabetes mellitus patients. Sanofi’s second-quarter sales of Lantus were up 16.3% to 1.56 billion euros ($2.02 billion).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK